Meda Denies Sun Merger Talks, Expands Dymista Tie With Cipla
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma's alleged acquisition target, Sweden's Meda, issued a strong denial it was discussing a merger with any company, despite the widely reported intention of the India drug maker.